Royal Statistical Society, 12 Errol Street, London, EC1Y 8LX and web-conference.
At the meeting the membership will learn about the terms of the proposed merger between PSI and the RSS and have the opportunity to ask questions of PSI directors involved in merger discussions and of representatives of the RSS.
PSI members will be asked to vote on a proposed merger between RSS and PSI at an extraordinary general meeting in September.
Under the proposed terms of the merger, PSI would become the Pharmaceutical Statistics Section of the RSS. More details, including those terms and answers to frequently asked questions are available on the PSI website.
The meeting will be divided into two parts: one will be a presentation of information relevant to the merger and the second will be a formal debate of the merger. Attendees are welcome to contribute speeches to the debate. In order to allow participation from the maximum number of attendees, those making contributed speeches are asked to keep to two minutes speaking. To help the meeting run smoothly, please register your interest in speaking in advance with the meeting chair or at the PSI email address (email@example.com). Speakers who have given notice in advance will be given first preference on the night.
10 minute review of the agenda and rules for debate
Background to the merger
• 10 minute presentation of PSI’s state-of-the-nation and strategy (as it stood before the JAC discussions)
• 10 minutes presentation of RSS (strategy and structure)
• 10 minute presentation of proposed charter
Any materials presented will be made available in advance on the PSI website.
Debate (Chair: Katherine Hutchinson)
25 minutes of formal speeches: 4x6 minute speeches (2 x pro, 2 x anti) debating whether or not PSI should merge into the RSS
20-35 minutes of contributed speeches: up to 15x2 minute speeches taken from the floor/phone lines
10 minutes of formal rebuttal: 2x5 minute rebuttal/summary speeches from the debaters (1 x pro, 1 x anti).
Final Q&A and closeout
10 minutes of questions to JAC, PSI BoD, RSS representatives about issues raised by discussion
Summary by the chair of next steps
Standing orders for the debate Timing: 6 minute speeches for invited speakers, with 30 seconds maximum overrun strictly enforced. Two minutes for contributed speakers, with no overrun. One bite at the cherry: with the exception of the one rebuttal speech for each side and interruptions (see below) each speaker can only speak once. If there is time left over at the end, repeat contributions will be solicited by the chair. Interruptions:
• attendees can offer questions/comments by raising their hand.
• Speakers are not obliged to cede the floor.
• If a comment is accepted, it should be <15 seconds long.
• No interruptions can be offered during an (invited/contributed) speaker’s first and last minute (/30 seconds) Rebuttal speeches: these should aim to answer questions raised during the debate or challenge arguments made by the opposing side. They should not bring up new material or arguments unless necessary to make a rebuttal.
PSI New Starters Half-Day Networking Event
An opportunity to meet statisticians from across the pharmaceutical industry in a relaxed and informal setting. An exciting program of events and a chance to work in small groups on a data analysis challenge. Lunch provided.
A Non-PSI Event - Protecting confidentiality and privacy in clinical trial and medical data sets
We are increasingly living in a data driven world. Data are collected in many different ways for a variety of purposes. As such, concerns around protecting the privacy of individuals have increased in recent times.
A PSI Training Course - Practical Approaches to Designing Adaptive Clinical Trials
This hands-on course will provide a deep dive into 4 software packages used to design adaptive clinical trials.
The course will start by providing a general overview of adaptive designs, explaining the different type of adaptations possible and the benefits of each design. Following this, participants will be given the opportunity to have a go at designing trials in R (using RPACTS), EAST, FACTS, and nQuery.
PSI Training Course - Bayesian Practical Course using R and SAS
This practical training course will give a deep dive into performing Bayesian analyses in R and SAS. It is aimed at statisticians who need to be able to conduct Bayesian analyses as part of their day to day work. By the end of the course participants will be able to conduct their own analyses.
This webinar will address operational issues of paramount importance within the healthcare industry with a view to using statistics for the benefit of patients. In attending this webinar, you'll hear more about work being conducted to address some operational issues we face in the health care industrys e.g. patient rectuitment, drug supply and meeting NHS 18 week targets.
PSI Toxicology SIG workshop – 16th and 17th March 2020
The Toxicology SIG provides a forum for statisticians working in regulatory/investigative toxicology, as well as most other pre-clinical areas, to discuss issues and interact with one another.
This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types.
The afternoon of Day 1 will include a 4.5 hour Bayesian training course focused towards applications in toxicology/pre-clinical, provided by Prof. Dr. Katja Ickstadt and is included in the workshop fee.
The cost will be £270 including VAT per delegate, inclusive of food and one night’s accommodation (and the training course). The workshop is being held at the Crowne Plaza Hotel, Heathrow.
The agenda and topics that will be discussed are yet to be finalised, but please get in touch with firstname.lastname@example.org if you have suggestions. Full details will be circulated in the coming weeks.
This course is aimed at Statisticians and Programmers experienced in SAS, but little or no experience with R.
An Introduction to R studio and the R language, statistical graphics, programming statistical models, simulations and more…
Non-proportional hazards and applications in immuno-oncology
Designs of clinical trials with time to event primary endpoints usually rely on hazards being constant over time. A major challenge in immuno-oncology is the delayed onset of benefit with such therapies and the presence of non-proportional hazards. The impact of this needs to be accounted for in sample size calculations, analysis methodology and reporting. At this meeting, we will examine possible strategies to handle such features, which may not be fully known when the trial is initiated.
The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2020 to July 2021 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 - 4 sessions in the UK. It promises to be a truly memorable course.